Skip to main content

Table 2 Relative risks for PSA relapse-free survival according to the studied variables

From: Outcomes of high-dose intensity-modulated radiotherapy alone with 1 cm planning target volume posterior margin for localized prostate cancer

Variable

RR

95% CI

Total

PSA relapse

%

p

Stage

     

0.058

 T1a/T1b/T1c

1.00

 

73

5

6.8

 

 T2a/T2b/T2c

2.91

1.04 – 8.17

62

13

21.0

 

 T3a/T3b

6.02

0.67 – 54.22

5

1

20.0

 

Gleason score

     

0.774

 ≤ 6

1.00

 

53

6

11.3

 

 7

1.08

0.37 – 3.12

56

8

14.3

 

 8 – 10

1.50

0.46 – 4.94

31

5

16.1

 

PSA

     

0.493

 < 10

1.00

 

106

13

12.3

 

 10 – 19.9

1.74

0.61 – 4.97

28

5

17.9

 

 ≥ 20

2.07

0.27 – 16.21

6

1

16.7

 

NCCN Risk Group

     

0.331

 Low

1.00

 

36

3

8.3

 

 Intermediate

1.61

0.43 – 5.94

64

9

14.1

 

 High

2.62

0.67 – 10.16

40

7

17.5

 

Age (years)

     

0.324

 < 60

1.00

 

21

2

9.5

 

 ≥ 60 e < 75

2.15

0.48 – 9.49

86

15

17.4

 

 ≥ 75

0.89

0.12 – 6.53

33

2

6.1

 

Total

  

140

19

13.6

 
  1. Abbreviations: NCCN = National Comprehensive Cancer Network; PSA = prostate-specific antigen; RR = relative risk; CI = confidence interval.